CARLSBAD, Calif., Dec. 18, 2018 /PRNewswire/ -- Qualigen, Inc., and Advanced Cancer Therapeutics, LLC (ACT) today announced
"We are delighted to add ACT-GRO-777/AS1411 to our portfolio of anticancer drug technologies. This is a unique opportunity to continue development of a compound that has already undergone extensive preclinical characterization and shown promise in prior clinical studies. We believe that Qualigen's new AS1411-GNP formulation will lead to a significant improvement in potency and absorption in humans, enabling the drug to fulfill the promise seen in the earlier studies," noted Michael S. Poirier, Chairman, CEO and President of Qualigen.
"We are excited to work with Qualigen on the product development of our aptamer-based drug to fight cancer," said Randall Riggs, Board Member of ACT.
About Qualigen, Inc.Qualigen, Inc. is a medical device company focused on the development, production and commercialization of innovative medical technologies, including its flagship FastPack® point-of-care immunoassay system and novel therapeutic technologies for treatment of cancers and infectious diseases. For more information, visit www.qualigeninc.com.
View original content:http://www.prnewswire.com/news-releases/qualigen-obtains-exclusive-license-to-novel-cancer-drug-technology-from-advanced-cancer-therapeutics-300768398.html
SOURCE Qualigen, Inc.
Subscribe to our Free Newsletters!